Plasma Levels of Matrix Metalloprotease MMP-9 and Tissue Inhibitor TIMP-1 in Caucasian Patients with Polypoidal Choroidal Vasculopathy.
biomarker
matrix metalloproteinase
plasma
polypoidal choroidal vasculopathy
Journal
Vision (Basel, Switzerland)
ISSN: 2411-5150
Titre abrégé: Vision (Basel)
Pays: Switzerland
ID NLM: 101733282
Informations de publication
Date de publication:
15 May 2020
15 May 2020
Historique:
received:
20
03
2020
revised:
08
05
2020
accepted:
13
05
2020
entrez:
21
5
2020
pubmed:
21
5
2020
medline:
21
5
2020
Statut:
epublish
Résumé
Matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) are regulating enzymes of the extracellular matrix. A systemic imbalance of MMP-9 and TIMP-1, thought to reflect an imbalance of the extracellular matrix homeostasis, is previously associated with polypoidal choroidal vasculopathy (PCV) in Asian patients. Previous studies suggest inter-ethnical differences in the genetic background and etiology of PCV. To further explore this issue, we studied the plasma levels of MMP-9 and TIMP-1 in Caucasian patients with PCV and compared to healthy age-matched controls. For this prospective case-control study, 60 participants were recruited who were either patients with PCV ( Plasma levels of MMP-9 ( We demonstrate that Caucasian patients with PCV do not have altered levels of plasma MMP-9 or plasma TIMP-1. These findings suggest no strong evidence of a systemic imbalance of the extracellular matrix homeostasis in Caucasian patients with PCV. Our findings are in line with studies of other aspects of PCV that are also subject to significant inter-ethnical differences.
Sections du résumé
BACKGROUND
BACKGROUND
Matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) are regulating enzymes of the extracellular matrix. A systemic imbalance of MMP-9 and TIMP-1, thought to reflect an imbalance of the extracellular matrix homeostasis, is previously associated with polypoidal choroidal vasculopathy (PCV) in Asian patients. Previous studies suggest inter-ethnical differences in the genetic background and etiology of PCV. To further explore this issue, we studied the plasma levels of MMP-9 and TIMP-1 in Caucasian patients with PCV and compared to healthy age-matched controls.
METHODS
METHODS
For this prospective case-control study, 60 participants were recruited who were either patients with PCV (
RESULTS
RESULTS
Plasma levels of MMP-9 (
CONCLUSION
CONCLUSIONS
We demonstrate that Caucasian patients with PCV do not have altered levels of plasma MMP-9 or plasma TIMP-1. These findings suggest no strong evidence of a systemic imbalance of the extracellular matrix homeostasis in Caucasian patients with PCV. Our findings are in line with studies of other aspects of PCV that are also subject to significant inter-ethnical differences.
Identifiants
pubmed: 32429088
pii: vision4020027
doi: 10.3390/vision4020027
pmc: PMC7356191
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Danish Eye Research Foundation
ID : -
Organisme : Fight for Sight Denmark
ID : -
Organisme : Københavns Universitet
ID : -
Organisme : Velux Fonden
ID : -
Références
Clin Biochem. 2008 Dec;41(18):1466-73
pubmed: 18926810
Graefes Arch Clin Exp Ophthalmol. 2017 Feb;255(2):311-316
pubmed: 27534663
Prog Retin Eye Res. 2010 Jan;29(1):19-29
pubmed: 19854291
Arch Ophthalmol. 2003 Oct;121(10):1392-6
pubmed: 14557174
J Neuroimmunol. 2005 May;162(1-2):1-2
pubmed: 15833353
Clin Ophthalmol. 2014;8:15-21
pubmed: 24363550
Br J Ophthalmol. 2002 Oct;86(10):1093-8
pubmed: 12234885
Am J Ophthalmol Case Rep. 2017 Oct 04;11:176-180
pubmed: 30128371
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4729-37
pubmed: 18586873
Clin Exp Ophthalmol. 2018 Mar;46(2):189-200
pubmed: 29178419
Ophthalmol Ther. 2020 Jun;9(2):329-342
pubmed: 32279234
Graefes Arch Clin Exp Ophthalmol. 2017 Mar;255(3):493-502
pubmed: 27628062
Invest Ophthalmol Vis Sci. 2011 Nov 11;52(12):8780-4
pubmed: 22003121
JAMA Ophthalmol. 2019 May 1;137(5):515-522
pubmed: 30844038
Clin Exp Ophthalmol. 2018 Aug;46(6):661-669
pubmed: 29360187
Clin Chem Lab Med. 2006;44(4):503-4
pubmed: 16599849
Int J Cancer. 2007 Jul 1;121(1):216-8; author reply 219-23
pubmed: 17315186
Immun Ageing. 2019 Aug 15;16:20
pubmed: 31428180
Acta Ophthalmol. 2018 Aug;96(5):475-480
pubmed: 29193780
J Clin Med. 2015 Apr 24;4(5):782-821
pubmed: 26239448
Acta Ophthalmol. 2018 Feb;96(1):e94-e95
pubmed: 28636275
Clin Chem. 2001 Jan;47(1):28-30
pubmed: 11148173
Am J Pathol. 2017 Dec;187(12):2841-2857
pubmed: 28941979
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1101-5
pubmed: 18326737
Acta Ophthalmol. 2019 Feb;97(1):99-106
pubmed: 30288946
Dan Med J. 2016 Nov;63(11):
pubmed: 27808038
Ther Adv Ophthalmol. 2019 Feb 27;11:2515841419831152
pubmed: 30834360
Retina. 2000;20(6):650-4
pubmed: 11131419
Retina. 2018 Dec;38(12):2363-2371
pubmed: 29059101
Sports Med. 2015 Feb;45(2):269-78
pubmed: 25252612
Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2583-2590
pubmed: 31219532
Mol Vis. 2013;19:729-36
pubmed: 23559867
Retin Cases Brief Rep. 2017 Winter;11 Suppl 1:S128-S131
pubmed: 27930435
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5242-5250
pubmed: 29049725
Ophthalmic Genet. 2011 Jun;32(2):80-2
pubmed: 21391811